RetinaCME
LECTURECME

Inflammation Overload: Advances in Multimodal Therapy for Diabetic Eye Disease

Author(s)/Faculty: Rishi P. Singh, MD; Jay S. Duker, MD; Baruch D. Kuppermann, MD, PhD
Release Date: 12/8/2016Expiration Date: 12/7/2018
Credit Type: CMENumber of Credits: 1.5
Content Type: LectureProvider: Vindico Medical Education
Diabetic macular edema, which is a manifestation of diabetic retinopathy, affects approximately 750,000 people in the United States and is a leading cause of vision loss. In recent years, there has been a revolutionary paradigm shift in the treatment of diabetic retinopathy. Intravitreal therapy has rapidly supplanted focal/grid laser as the standard of care, while the role of angiogenesis and inflammation in the pathogenesis of diabetic retinopathy has been elucidated. In addition, the development of new delivery systems for anti-vascular endothelial growth factor (VEGF) therapy and steroids offers improved characteristics that make them valuable additions to the armamentarium. This CME activity will review the role of angiogenesis and inflammation in the pathogenesis of diabetic eye disease and assess current and emerging therapies for diabetic retinal disease, as well as alternative treatments for patients who do not respond to initial anti-VEGF therapy, to improve the standard of care for this sight-threatening disease.